StockData
Prelude Therapeutics Inc logo

Prelude Therapeutics Inc (PRLD) stock

PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/3058% above fair value
$3.41−0.04 (-1.16%)

Close on Nov 16, 2026Market cap $272.13MP/E –Yield –

Prelude Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Prelude Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -269.7%. For fiscal 2025 it was -819.6%, against -1816.8% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-819.6%+997.2
FY2024Dec 31, 2024-1816.8%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-244.1%+474.2
Q1 FY2026Mar 31, 2026-226.7%+849.0
Q4 FY2025Dec 31, 2025-291.8%–
Q3 FY2025Sep 30, 2025-303.5%–
Q4 FY2024Dec 31, 2024-718.3%–
Q3 FY2024Sep 30, 2024-1075.7%–

More Prelude Therapeutics figures

See a number that looks wrong?